NTLA241220P17500
- 4.50
- 0.000.00%
Intellia Therapeutics Newsroom
Cathie Wood Sees $400B Opportunity In Biologics — How Have Her Bets Fared?
NTLA Up as FDA Grants RMAT Status to Genome-Editing Therapy
JonesTrading Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Maintains Target Price $40
Promising Outlook for Intellia Therapeutics' Nex-z in ATTR-CM Treatment Backed by Safety and Patient Interest
Sector Update: Health Care Stocks Rise in Monday Afternoon Trading
Intellia Therapeutics' Nex-z Receives FDA Regenerative Medicine Advanced Therapy Designation
Intellia's Single-Dose Gene Editing Treatment for ATTR Amyloidosis Gets FDA Fast-Track Approval Boost
Express News | Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (Rmat) Designation Granted to Nexiguran Ziclumeran (Nex-Z) for the Treatment of Hereditary Transthyretin (Attr) Amyloidosis With Polyneuropathy
Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (Nex-z) for the Treatment of Hereditary Transthyretin (ATTR) Amyloidosis With Polyneuropathy
Pfizer Meets Amyloidosis Rival as BridgeBio Wins FDA Nod for Attruby
Down 33% in 1 Month, Should You Buy the Dip With Intellia Therapeutics Stock?
Cathie Wood's ARK Investment Buys 223.5K Shares of Intellia Therapeutics Today
A Quick Look at Today's Ratings for Intellia Therapeutics(NTLA.US), With a Forecast Between $60 to $90
Positive Buy Rating for Intellia Therapeutics Amid Promising Trial Results for Nex-z in ATTR-CM
Intellia Therapeutics Price Target Lowered to $70 From $80 at Wells Fargo
Intellia Therapeutics' NTLA-2001 Shows Promising Potential With Positive Phase 1 Data and Accelerated Phase 3 Enrollment
Intellia Therapeutics Price Target Cut to $70.00/Share From $80.00 by Wells Fargo
Intellia Therapeutics Is Maintained at Overweight by Wells Fargo
Intellia Therapeutics Price Target Maintained With a $14.00/Share by Wedbush
Chardan Capital Maintains Buy on Intellia Therapeutics, Raises Price Target to $91